Macular HolesMICAINCT05747144
Multimodal Imaging in Vitreo-retinal Surgery and Macular Dystrophies
An observational study of Macular Holes and Epiretinal Membrane, run by Fondazione Policlinico Universitario Agostino Gemelli IRCCS at 1 site in Italy.
Trial summary
The aim of the study is to identify morphological and functional biomarkers of post-operative recovery after vitreoretinal surgery, using decisional support systems (DSS), based on multimodal big-data analysis by means of machine learning techniques in daily clinical practice Read more about this study
- Who is it for?
- Ages 18 months and older
- Conditions the study is for
- Macular Holes, Epiretinal Membrane, Retinal Detachment
- What is being tested?
- Biometry, Retinography (Color) + Autofluorescence (AF) and OCT B-scan and OCT angiography (OCTA)
- How many people
- 100 participants
- Where
- 1 siteItaly
- Study dates
- 15 Jan 2021to 16 Jan 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 months and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: All patients to undergo vitreo-retinal surgery for macular disease (i.e.Macular hole, epiretinal membranes, Retinal detachment, Macular dystrophies (retinal pre-prosthesis).
Who may be able to join
- All patients to undergo vitreo-retinal surgery for:
- Macular hole
- Epiretinal membranes
- Retinal detachment
- Macular dystrophies (retinal pre-prosthesis)
Who cannot join
- Patients under 18 years of age will be excluded; patients in whom morphological examinations cannot be performed due to poor cooperation or opacity of the dioptric media (e.g. corneal pathology). Quality of morphological images inadequate for post acquisition processing (<6/10).
Trial locations and contacts
1 site in 1 country.
Alfonso Savastano, MD,PhD contact
Italy1 site, 1 recruiting
- Recruiting
Prof. Stanislao Rizzo
Rome, 00168
Stanislao Rizzo, MD,PhD
About this study
Official title: Multimodal Imaging in Vitreo-retinal Surgery and Macular Dystrophies: Biomarkers of Morpho-Functional Recovery by Artificial Intelligence
The aim of the study is to identify morphological and functional biomarkers of post-operative recovery after vitreoretinal surgery, using decisional support systems (DSS), based on multimodal big-data analysis by means of machine learning techniques in daily clinical practice
Read the detailed description
The aim of the study is to identify morphological and functional biomarkers of post-operative recovery after vitreoretinal surgery. Identifying the biomarkers and assessing the predictivity of recovery will make it possible to highlight the categories of patients who can benefit most from surgical treatment, and to target the patient more precisely for personalised medicine and surgery. The introduction of new decisional support systems (DSS), based on multimodal big-data analysis through machine learning techniques in daily clinical practice, is providing new useful information in patient assessment for personalised surgery.
- Being tested
- Biometry, Retinography (Color) + Autofluorescence (AF), OCT B-scan and OCT angiography (OCTA), Microperimetry, Electrophysiological exams
- Keywords
- vitreoretinal surgery, machine learning, decisional support systems
- Medical subject headings
- Retinal Perforations, Epiretinal Membrane, Retinal Detachment, Macular Degeneration
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
BiometryDiagnostic test
Biometric measurements performed with IOL Master, if executable Contact or immersion echobiometry if IOL Master cannot be performed
Retinography (Color) + Autofluorescence (AF)Diagnostic test
Colour + AF: EIDON, if available (60° not modulable) Colour: COBRA (60° non-modifiable) AF: Spectralis-Heidelberg (choose 55°) Other if available (choose posterior pole examination between 50-60°)
OCT B-scan and OCT angiography (OCTA)Diagnostic test
OCT B-scan:
2 scans (6 mm)
1 cross line
OCTA:
3x3 mm + 6x6 mm centred on the fovea 4.5 mm centred on the optic nerve
MicroperimetryDiagnostic test
- fixation pattern 2) retinal sensitivity map
Electrophysiological examsDiagnostic test
Layer-by-layer assessment of the retina using focal ERG and pattern ERG according to standardised and published methods , For patients with visus < 3/10 and unstable fixation a protocol based on component analysis of the photopic ERG from diffuse flash will be used.
| Study group | Role | What they receive |
|---|---|---|
| Macular hole | Patients affected by macular hole. Receives: Diagnostic Test: Biometry; Diagnostic Test: Retinography (Color) + Autofluorescence (AF); Diagnostic Test: OCT B-scan and OCT angiography (OCTA); Diagnostic Test: Microperimetry; Diagnostic Test: Electrophysiological exams | |
| Epiretinal membranes | Patients affected by epiretinal membrane. Receives: Diagnostic Test: Biometry; Diagnostic Test: Retinography (Color) + Autofluorescence (AF); Diagnostic Test: OCT B-scan and OCT angiography (OCTA); Diagnostic Test: Microperimetry; Diagnostic Test: Electrophysiological exams | |
| Retinal detachment | Patients affected by retinal detachment. Receives: Diagnostic Test: Biometry; Diagnostic Test: Retinography (Color) + Autofluorescence (AF); Diagnostic Test: OCT B-scan and OCT angiography (OCTA); Diagnostic Test: Microperimetry; Diagnostic Test: Electrophysiological exams | |
| Macular dystrophies | Patients affected by macular dystrophies. Receives: Diagnostic Test: Biometry; Diagnostic Test: Retinography (Color) + Autofluorescence (AF); Diagnostic Test: OCT B-scan and OCT angiography (OCTA); Diagnostic Test: Microperimetry; Diagnostic Test: Electrophysiological exams |
What is being measured
The primary outcome is the main question the study is designed to answer.
Predictivity of morphological-functional radiomic data
Rate of predictivity of morphological-functional radiomic data to establish the grade of recovery in the post-operative period by means of an artificial intelligence (AI) machine learning model.
Measured: 3 years
Secondary outcomes (3)
Identify predictive differences according to diagnosis
Subdivision into subgroups in order to identify predictive differences according to diagnosis
Measured: 3 years
Correlating with the age of patients
Identify predictive differences according to diagnosis and correlate them with the age of patients
Measured: 3 years
Correlate with age of onset of disease
Identify predictive differences according to diagnosis and correlate them with the age of onset of disease
Measured: 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Feb 2023
- Study start15 Jan 2021
- Primary completion15 Jan 2025 (estimated)
- Study completion16 Jan 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (41)Papers the sponsor has linked to this study.
- Other trials for Macular HolesStudies of the same condition, open and under way.
- More trials run by Fondazione Policlinico Universitario Agostino Gemelli IRCCSThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, RIZZO STANISLAO, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05747144
- Sponsor's protocol ID
- 3680
- Acronym
- MICAI
- Status last verified
- Feb 2024
- First submitted
- 17 Feb 2023
- Last updated
- 13 Feb 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Garrity ST, Sarraf D, Freund KB, Sadda SR. Multimodal Imaging of Nonneovascular Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2018 Mar 20;59(4):AMD48-AMD64. doi: 10.1167/iovs.18-24158.
PubMed 30025107Acon D, Wu L. Multimodal Imaging in Diabetic Macular Edema. Asia Pac J Ophthalmol (Phila). 2018 Jan-Feb;7(1):22-27. doi: 10.22608/APO.2017504. Epub 2017 Jan 29.
PubMed 29376234Duker JS, Kaiser PK, Binder S, de Smet MD, Gaudric A, Reichel E, Sadda SR, Sebag J, Spaide RF, Stalmans P. The International Vitreomacular Traction Study Group classification of vitreomacular adhesion, traction, and macular hole. Ophthalmology. 2013 Dec;120(12):2611-2619. doi: 10.1016/j.ophtha.2013.07.042. Epub 2013 Sep 17.
PubMed 24053995Spaide RF, Fujimoto JG, Waheed NK, Sadda SR, Staurenghi G. Optical coherence tomography angiography. Prog Retin Eye Res. 2018 May;64:1-55. doi: 10.1016/j.preteyeres.2017.11.003. Epub 2017 Dec 8.
PubMed 29229445Sun P, Tandias RM, Yu G, Arroyo JG. SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY FINDINGS AND VISUAL OUTCOME AFTER TREATMENT FOR VITREOMACULAR TRACTION. Retina. 2019 Jun;39(6):1054-1060. doi: 10.1097/IAE.0000000000002116.
PubMed 29595569Lee CS, Tyring AJ, Deruyter NP, Wu Y, Rokem A, Lee AY. Deep-learning based, automated segmentation of macular edema in optical coherence tomography. Biomed Opt Express. 2017 Jun 23;8(7):3440-3448. doi: 10.1364/BOE.8.003440. eCollection 2017 Jul 1.
PubMed 28717579Zur D, Iglicki M, Busch C, Invernizzi A, Mariussi M, Loewenstein A; International Retina Group. OCT Biomarkers as Functional Outcome Predictors in Diabetic Macular Edema Treated with Dexamethasone Implant. Ophthalmology. 2018 Feb;125(2):267-275. doi: 10.1016/j.ophtha.2017.08.031. Epub 2017 Sep 19.
PubMed 28935399Beam AL, Kohane IS. Big Data and Machine Learning in Health Care. JAMA. 2018 Apr 3;319(13):1317-1318. doi: 10.1001/jama.2017.18391. No abstract available.
PubMed 29532063Ngiam KY, Khor IW. Big data and machine learning algorithms for health-care delivery. Lancet Oncol. 2019 May;20(5):e262-e273. doi: 10.1016/S1470-2045(19)30149-4.
PubMed 31044724Abramoff MD, Lou Y, Erginay A, Clarida W, Amelon R, Folk JC, Niemeijer M. Improved Automated Detection of Diabetic Retinopathy on a Publicly Available Dataset Through Integration of Deep Learning. Invest Ophthalmol Vis Sci. 2016 Oct 1;57(13):5200-5206. doi: 10.1167/iovs.16-19964.
PubMed 27701631Gulshan V, Peng L, Coram M, Stumpe MC, Wu D, Narayanaswamy A, Venugopalan S, Widner K, Madams T, Cuadros J, Kim R, Raman R, Nelson PC, Mega JL, Webster DR. Development and Validation of a Deep Learning Algorithm for Detection of Diabetic Retinopathy in Retinal Fundus Photographs. JAMA. 2016 Dec 13;316(22):2402-2410. doi: 10.1001/jama.2016.17216.
PubMed 27898976Lakhani P, Sundaram B. Deep Learning at Chest Radiography: Automated Classification of Pulmonary Tuberculosis by Using Convolutional Neural Networks. Radiology. 2017 Aug;284(2):574-582. doi: 10.1148/radiol.2017162326. Epub 2017 Apr 24.
PubMed 28436741Esteva A, Kuprel B, Novoa RA, Ko J, Swetter SM, Blau HM, Thrun S. Dermatologist-level classification of skin cancer with deep neural networks. Nature. 2017 Feb 2;542(7639):115-118. doi: 10.1038/nature21056. Epub 2017 Jan 25.
PubMed 28117445Ting DSW, Cheung CY, Lim G, Tan GSW, Quang ND, Gan A, Hamzah H, Garcia-Franco R, San Yeo IY, Lee SY, Wong EYM, Sabanayagam C, Baskaran M, Ibrahim F, Tan NC, Finkelstein EA, Lamoureux EL, Wong IY, Bressler NM, Sivaprasad S, Varma R, Jonas JB, He MG, Cheng CY, Cheung GCM, Aung T, Hsu W, Lee ML, Wong TY. Development and Validation of a Deep Learning System for Diabetic Retinopathy and Related Eye Diseases Using Retinal Images From Multiethnic Populations With Diabetes. JAMA. 2017 Dec 12;318(22):2211-2223. doi: 10.1001/jama.2017.18152.
PubMed 29234807Li Z, He Y, Keel S, Meng W, Chang RT, He M. Efficacy of a Deep Learning System for Detecting Glaucomatous Optic Neuropathy Based on Color Fundus Photographs. Ophthalmology. 2018 Aug;125(8):1199-1206. doi: 10.1016/j.ophtha.2018.01.023. Epub 2018 Mar 2.
PubMed 29506863
Study at a glance
From the registry record, last updated by the sponsor on 13 Feb 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Multimodal Imaging in Vitreo-retinal Surgery and Macular Dystrophies: Biomarkers of Morpho-Functional Recovery by Artificial Intelligence
- ClinicalTrials.gov ID
- NCT05747144
- Acronym / sponsor ID
- MICAI / 3680
- Keywords
- vitreoretinal surgery, machine learning, decisional support systems
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCSUniversity, hospital or other
- Study start
- 15 Jan 2021 (actual)
- Primary completion
- 15 Jan 2025 (estimated)
- Study completion
- 16 Jan 2025 (estimated)
- First posted
- 28 Feb 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the study is to identify morphological and functional biomarkers of post-operative recovery after vitreoretinal surgery, using decisional support systems (DSS), based on multimodal big-data analysis by means of machine learning techniques in daily clinical practice
Detailed description
The aim of the study is to identify morphological and functional biomarkers of post-operative recovery after vitreoretinal surgery. Identifying the biomarkers and assessing the predictivity of recovery will make it possible to highlight the categories of patients who can benefit most from surgical treatment, and to target the patient more precisely for personalised medicine and surgery. The introduction of new decisional support systems (DSS), based on multimodal big-data analysis through machine learning techniques in daily clinical practice, is providing new useful information in patient assessment for personalised surgery.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Macular hole | – | Diagnostic Test: Biometry, Diagnostic Test: Retinography (Color) + Autofluorescence (AF), Diagnostic Test: OCT B-scan and OCT angiography (OCTA), Diagnostic Test: Microperimetry, Diagnostic Test: Electrophysiological examsPatients affected by macular hole. |
| Epiretinal membranes | – | Diagnostic Test: Biometry, Diagnostic Test: Retinography (Color) + Autofluorescence (AF), Diagnostic Test: OCT B-scan and OCT angiography (OCTA), Diagnostic Test: Microperimetry, Diagnostic Test: Electrophysiological examsPatients affected by epiretinal membrane. |
| Retinal detachment | – | Diagnostic Test: Biometry, Diagnostic Test: Retinography (Color) + Autofluorescence (AF), Diagnostic Test: OCT B-scan and OCT angiography (OCTA), Diagnostic Test: Microperimetry, Diagnostic Test: Electrophysiological examsPatients affected by retinal detachment. |
| Macular dystrophies | – | Diagnostic Test: Biometry, Diagnostic Test: Retinography (Color) + Autofluorescence (AF), Diagnostic Test: OCT B-scan and OCT angiography (OCTA), Diagnostic Test: Microperimetry, Diagnostic Test: Electrophysiological examsPatients affected by macular dystrophies. |
Who may qualify
- Ages
- 18 months and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- All patients to undergo vitreo-retinal surgery for macular disease (i.e.Macular hole, epiretinal membranes, Retinal detachment, Macular dystrophies (retinal pre-prosthesis).
Key inclusion criteria (5 listed)
- All patients to undergo vitreo-retinal surgery for:
Key exclusion criteria (1 listed)
- Patients under 18 years of age will be excluded; patients in whom morphological examinations cannot be performed due to poor cooperation or opacity of the dioptric media (e.g. corneal pathology). Quality of morphological images inadequate for post acquisition processing (<6/10).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| BiometryBiometric measurements performed with IOL Master, if executable Contact or immersion echobiometry if IOL Master cannot be performed | Diagnostic test | Epiretinal membranes, Macular dystrophies, Macular hole, Retinal detachment |
| Retinography (Color) + Autofluorescence (AF)Colour + AF: EIDON, if available (60° not modulable) Colour: COBRA (60° non-modifiable) AF: Spectralis-Heidelberg (choose 55°) Other if available (choose posterior pole examination between 50-60°) | Diagnostic test | Epiretinal membranes, Macular dystrophies, Macular hole, Retinal detachment |
| OCT B-scan and OCT angiography (OCTA)OCT B-scan: 2 scans (6 mm) 1 cross line OCTA: 3x3 mm + 6x6 mm centred on the fovea 4.5 mm centred on the optic nerve | Diagnostic test | Epiretinal membranes, Macular dystrophies, Macular hole, Retinal detachment |
| Microperimetry1) fixation pattern 2) retinal sensitivity map | Diagnostic test | Epiretinal membranes, Macular dystrophies, Macular hole, Retinal detachment |
| Electrophysiological examsLayer-by-layer assessment of the retina using focal ERG and pattern ERG according to standardised and published methods , For patients with visus < 3/10 and unstable fixation a protocol based on component analysis of the photopic ERG from diffuse flash will be used. | Diagnostic test | Epiretinal membranes, Macular dystrophies, Macular hole, Retinal detachment |
Primary outcome
Predictivity of morphological-functional radiomic data
Time frame: 3 years
Rate of predictivity of morphological-functional radiomic data to establish the grade of recovery in the post-operative period by means of an artificial intelligence (AI) machine learning model.
3 secondary outcomes
Identify predictive differences according to diagnosis
Time frame: 3 years
Correlating with the age of patients
Time frame: 3 years
Correlate with age of onset of disease
Time frame: 3 years
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Feb 2024.
- Background: PubMed 30025107Garrity ST, Sarraf D, Freund KB, Sadda SR. Multimodal Imaging of Nonneovascular Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2018 Mar 20;59(4):AMD48-AMD64. doi: 10.1167/iovs.18-24158.
- Background: PubMed 29376234Acon D, Wu L. Multimodal Imaging in Diabetic Macular Edema. Asia Pac J Ophthalmol (Phila). 2018 Jan-Feb;7(1):22-27. doi: 10.22608/APO.2017504. Epub 2017 Jan 29.
- Background: PubMed 24053995Duker JS, Kaiser PK, Binder S, de Smet MD, Gaudric A, Reichel E, Sadda SR, Sebag J, Spaide RF, Stalmans P. The International Vitreomacular Traction Study Group classification of vitreomacular adhesion, traction, and macular hole. Ophthalmology. 2013 Dec;120(12):2611-2619. doi: 10.1016/j.ophtha.2013.07.042. Epub 2013 Sep 17.
- Background: PubMed 29229445Spaide RF, Fujimoto JG, Waheed NK, Sadda SR, Staurenghi G. Optical coherence tomography angiography. Prog Retin Eye Res. 2018 May;64:1-55. doi: 10.1016/j.preteyeres.2017.11.003. Epub 2017 Dec 8.
- Background: PubMed 29595569Sun P, Tandias RM, Yu G, Arroyo JG. SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY FINDINGS AND VISUAL OUTCOME AFTER TREATMENT FOR VITREOMACULAR TRACTION. Retina. 2019 Jun;39(6):1054-1060. doi: 10.1097/IAE.0000000000002116.
- Background: PubMed 28717579Lee CS, Tyring AJ, Deruyter NP, Wu Y, Rokem A, Lee AY. Deep-learning based, automated segmentation of macular edema in optical coherence tomography. Biomed Opt Express. 2017 Jun 23;8(7):3440-3448. doi: 10.1364/BOE.8.003440. eCollection 2017 Jul 1.
- Background: PubMed 28935399Zur D, Iglicki M, Busch C, Invernizzi A, Mariussi M, Loewenstein A; International Retina Group. OCT Biomarkers as Functional Outcome Predictors in Diabetic Macular Edema Treated with Dexamethasone Implant. Ophthalmology. 2018 Feb;125(2):267-275. doi: 10.1016/j.ophtha.2017.08.031. Epub 2017 Sep 19.
- Background: PubMed 29532063Beam AL, Kohane IS. Big Data and Machine Learning in Health Care. JAMA. 2018 Apr 3;319(13):1317-1318. doi: 10.1001/jama.2017.18391. No abstract available.
- Background: PubMed 31044724Ngiam KY, Khor IW. Big data and machine learning algorithms for health-care delivery. Lancet Oncol. 2019 May;20(5):e262-e273. doi: 10.1016/S1470-2045(19)30149-4.
- Background: PubMed 27701631Abramoff MD, Lou Y, Erginay A, Clarida W, Amelon R, Folk JC, Niemeijer M. Improved Automated Detection of Diabetic Retinopathy on a Publicly Available Dataset Through Integration of Deep Learning. Invest Ophthalmol Vis Sci. 2016 Oct 1;57(13):5200-5206. doi: 10.1167/iovs.16-19964.
- Background: PubMed 27898976Gulshan V, Peng L, Coram M, Stumpe MC, Wu D, Narayanaswamy A, Venugopalan S, Widner K, Madams T, Cuadros J, Kim R, Raman R, Nelson PC, Mega JL, Webster DR. Development and Validation of a Deep Learning Algorithm for Detection of Diabetic Retinopathy in Retinal Fundus Photographs. JAMA. 2016 Dec 13;316(22):2402-2410. doi: 10.1001/jama.2016.17216.
- Background: PubMed 28436741Lakhani P, Sundaram B. Deep Learning at Chest Radiography: Automated Classification of Pulmonary Tuberculosis by Using Convolutional Neural Networks. Radiology. 2017 Aug;284(2):574-582. doi: 10.1148/radiol.2017162326. Epub 2017 Apr 24.
- Individual participant dataSharing planned: No
Related trials for Macular Holes
RecruitingObservational study
Surgical Procedure Efficiency Evaluation stuDy
Cataract, Vitreous Hemorrhage
RecruitingObservational study
Intraoperative OCT Guidance of Intraocular Surgery II
Macular Holes, Epiretinal Membrane
Recruiting
Autologous Tenon's Capsule Graft for Refractory Macular Holes
Macular Hole Surgery
Active, not recruiting
Outcomes of Macular Hole Surgery With Inverted Flap With vs Without Post op Posturing With SF6 in Macular Hole More Than 400 Micrometres
Macular Hole
Recruiting
Comparative Study of Decellularized Human Amniotic Membrane Hydrogel and Inverted Internal Limiting Membrane Flap in Idiopathic Large Macular Holes
Macular Holes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Alfonso Savastano, MD,PhD contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Macular Holes and Epiretinal Membrane, run by Fondazione Policlinico Universitario Agostino Gemelli IRCCS at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 13 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Maria Cristina Savastano, MD,PhD (+39 3384443002, mariacristina.savastano@unicatt.it), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Predictivity of morphological-functional radiomic data (time frame: 3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05747144, which also lists 41 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Feb 2024.